Background: Inhaled nitric oxide (iNO) is used widely in newborn infants with hypoxic respiratory failure, despite the known and the oretical toxicity of iNO, and a relative lack of information about appropriate doses...Background: Inhaled nitric oxide (iNO) is used widely in newborn infants with hypoxic respiratory failure, despite the known and the oretical toxicity of iNO, and a relative lack of information about appropriate doses. Aim: To determine whether adose-response relationship existed for iNO in preterm infants.Design: A four-period, four-dose, cross-over design was used with iNO given for 15 min in a randomised sequence in concentrations of 5, 10, 20 and 40 parts per million (ppm), with a minimum 5 min wash-out period. Data on ventilatory, bloodgas and other physiological measurements were recorded before and at the end of each period. The relationship of clinical response with iNO dose and period was analysed using multivariate regression. Subjects: Infants with gestational age < 34 weeks and < 28 days postnatal age with hypoxic respiratory failure were recruited. Outcome measure: A clinically significant dose-response was defined as a rise in the post-ductalarterial oxygen tension (PaO2) of at least 3 kPa. Results:Thirteen infants were recruited. At trial entry, ten were < 3 days of age; 11 were being treated with high frequency oscillatory ventilation; median (inter-quartile range) gestational age 27 (25-29) weeks; birthweight 983 (765-1120) g; oxygenation index 27.1 (21.8-28.8). Six infants (46%) showed a clinically significant response. After adjusting for period and patient effect, no evidence for an overall dose effect was identified(likelihood ratio test, p = 0.34). Conclusion: No evidence of a dose-response relationship with iNO was found in this study of very preterm infants with respiratory failure.展开更多
文摘Background: Inhaled nitric oxide (iNO) is used widely in newborn infants with hypoxic respiratory failure, despite the known and the oretical toxicity of iNO, and a relative lack of information about appropriate doses. Aim: To determine whether adose-response relationship existed for iNO in preterm infants.Design: A four-period, four-dose, cross-over design was used with iNO given for 15 min in a randomised sequence in concentrations of 5, 10, 20 and 40 parts per million (ppm), with a minimum 5 min wash-out period. Data on ventilatory, bloodgas and other physiological measurements were recorded before and at the end of each period. The relationship of clinical response with iNO dose and period was analysed using multivariate regression. Subjects: Infants with gestational age < 34 weeks and < 28 days postnatal age with hypoxic respiratory failure were recruited. Outcome measure: A clinically significant dose-response was defined as a rise in the post-ductalarterial oxygen tension (PaO2) of at least 3 kPa. Results:Thirteen infants were recruited. At trial entry, ten were < 3 days of age; 11 were being treated with high frequency oscillatory ventilation; median (inter-quartile range) gestational age 27 (25-29) weeks; birthweight 983 (765-1120) g; oxygenation index 27.1 (21.8-28.8). Six infants (46%) showed a clinically significant response. After adjusting for period and patient effect, no evidence for an overall dose effect was identified(likelihood ratio test, p = 0.34). Conclusion: No evidence of a dose-response relationship with iNO was found in this study of very preterm infants with respiratory failure.
